Skip to content

A clinical trial of melatonin for the study of abdominal surgery patients with sepsis may develop multiorgan failure.

Prevention MODS by modulating the inflammatory response through melatonin administration in surgical patients with severe sepsis.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-006782-83-ES
Enrollment
Unknown
Registered
2013-05-16
Start date
2013-09-24
Completion date
Unknown
Last updated
2013-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic patients of abdominal surgery

Interventions

Product Name: MELATONIN INJECTABLE Pharmaceutical Form: Solution for injection INN or Proposed INN: Melatonin CAS Number: 73-31-4 Current Sponsor code: EC 08/00230 Other descriptive name: MELATONIN Co

Sponsors

Hospital Universitario Virgen de las Nieves
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are in clinical status from "severe sepsis" according to the diagnostic criteria "American College of Chest Physicians / Society of Critical Care Medicine" (Annex I), ie patients with systemic inflammatory response syndrome associated to infectious etiology dysfunction organic, hypoperfusion or hypotension, and will undergo surgery. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Age under 18 years, pregnancy, medical or surgical terminal disease, hepatic or chronic renal disease, psychiatric treatment or refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
Main Objective: Primary objective: To reduce the incidence of multiple organ dysfunction syndrome (MODS) in abdominal surgery patients with severe sepsis;Secondary Objective: Objective: 1) To study the inflammatory response by measuring cytokine index of lipid peroxidation (levels of malondialdehyde) in the study groups: melatonin, placebo and reference. 2) To evaluate clinical and immunological response resulting from administration of melatonin. 3) Evaluate the degree of organ dysfunction developed in the patients studied. 4) To study the correlation between the treatment given, the modulation of the parameters studied and the development of MODS.;Primary end point(s): ASSESSING inflammatory and immunological response: During the days 0 (pre-surgery and after administration of melatonin or placebo) and at 1, 2, 3, 4 and 5 days after the surgical intervention will be the determination of plasma levels of cytokines (IL-2, IL-4, IL -6, IL-10, TNF-a and IFN-g), and protein markers of apoptosis (sFas, FasL, sFasL, caspase-3, Bcl-2, and PARP), antioxidant enzymes (superoxide dismutase, SOD), catalase glutathione peroxidase and glutathione reductase) and the levels of lipid peroxidation (malondialdehyde). Also at the same time study will be conducted to determine blood count and differential count. Assessment of the functionality of various organic by biochemical systems in plasma obtained from blood samples parameters of transaminases (GOT, GPT, GGT), total and direct bilirubin, LDH, urea and creatinine. As levels of calcium, sodium, potassium and chloride.;Timepoint(s) of evaluation of this end point: Clinical evaluation: To evaluate the clinical outcome of patients and functional status of their organ systems in the days after surgery, was use the rating scale of multiple organ dysfunction syndrome associated with sepsis (SOFA) every 24 hours during the study period.

Secondary

MeasureTime frame
Secondary end point(s): ASSESSING inflammatory and immunological response: During the days 0 (pre-surgery and after administration of melatonin or placebo) and at 1, 2, 3, 4 and 5 days after the surgical intervention will be the determination of plasma levels of cytokines (IL-2, IL-4, IL -6, IL-10, TNF-a and IFN-g), and protein markers of apoptosis (sFas, FasL, sFasL, caspase-3, Bcl-2, and PARP), antioxidant enzymes (superoxide dismutase, SOD), catalase glutathione peroxidase and glutathione reductase) and the levels of lipid peroxidation (malondialdehyde). Also at the same time study will be conducted to determine blood count and differential count. Assessment of the functionality of various organic by biochemical systems in plasma obtained from blood samples parameters of transaminases (GOT, GPT, GGT), total and direct bilirubin, LDH, urea and creatinine. As levels of calcium, sodium, potassium and chloride.;Timepoint(s) of evaluation of this end point: Clinical evaluation: To evaluate the clinical outcome of patients and functional status of their organ systems in the days after surgery, was use the rating scale of multiple organ dysfunction syndrome associated with sepsis (SOFA) every 24 hours during the study period.

Countries

Spain

Contacts

Public ContactPablo Bueno Laraño

Hospital Universitario Virgen de las Nieves

pablo.bueno.exts@juntadeandalucia.es958020213

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026